🟢 Haemonetics is trading 5% up today after earnings beat and raised FY2027 guidance

Haemonetics is trading 5% up now at $87.79 after reporting first-quarter fiscal 2027 revenue of $339.4 million and adjusted EPS of $1.14, exceeding the $1.07 consensus estimate.

• Revenue increased 5.6% year over year.
• Management raised FY2027 revenue-growth guidance to 6%–9% and adjusted EPS guidance to $4.45–$4.75.
• Healthcare’s broader advance provides additional supportive sector context.